FDA Grants Expanded Indication for Linear Health Sciences’ Orchid Safety Release Valve

Innovative IV Dislodgement-Prevention Device is Now Approved for use with Blood or Blood Product Transfusions

OKLAHOMA CITY--()--Linear Health Sciences, a medical device company that has developed a proprietary, breakaway safety valve platform, today announced that it received an expanded indication for its Orchid Safety Release Valve (SRV) from the U.S. Food & Drug Administration (FDA).

The Orchid SRV™ is a sterile, single-use connector for needle-free access that makes return to treatment fast, simple, and clean, and improves both the patient and clinician experience. It is indicated for patients two weeks of age and older during intermittent or continuous infusion, and can now be used during the transfusion of blood or blood products.

“The Orchid SRV has been shown to significantly reduce IV dislodgement and its associated costs and complications,” said Rob Headley, vice president of sales and business development at Linear Health Sciences. “This, our third expanded indication, reflects a significant shift in the potential for a new gold standard of care, creates a valuable functional moat competitively, and expands our total addressable market exponentially.”

The estimated 25 million U.S. dislodgement events, which are most frequently caused by patient confusion or removal of the catheter, loose dressing or tape, and/or tubing becoming tangled in bed linens, are projected to cost $2 billion annually.1

“It’s crucial to protect IV access during blood administration for critical patients, to ensure a stable and uninterrupted flow of blood products, which can be life-saving,” said Jon Bell, MSN, RN, VA-BC, CEN, emergency department & cardiopulmonary services director at Mount Desert Island Hospital in Bar Harbor, Maine. “Orchid SRV can be used to safeguard the patient’s line even during blood administration, and is an innovative and valuable lifeguard for those who are already in a fragile condition.”

Linear Health Sciences earlier this year was awarded a contract by the U.S. Dept. of Veterans Affairs (VA) for the Orchid device, in partnership with GS2. Additionally, more than a dozen clinical sites have evaluated Orchid, with clinical acceptance rates averaging more than 92 percent. A growing number of hospitals and healthcare systems are evaluating the device, recognizing their need for the expanded protection that the Orchid SRV can provide.

One case study at a large, Northeast regional medical center showed annualized cost savings of nearly $104,000, and a clinical acceptance rate of more than 97 percent, leading to the whole-house adoption of the Orchid SRV.

“Approval for blood transfusion is a huge step forward,” said Dennis Woo, RN, interventional vascular access specialist. “Reducing instances of catheter hub exchange for procedures as common as transfusion will greatly minimize exposure in the hematology/oncology population, while continuing to reduce risk of IV loss.”

The Orchid SRV has also received an Innovative Technology contract from Vizient, Inc., the nation’s largest member-driven healthcare performance improvement company, and was recently awarded a national group purchasing agreement for the IV Therapy - Needleless Connectors category with Premier, Inc.

About Linear Health Sciences

Linear Health Sciences is a medical device company that has developed a proprietary, breakaway safety valve technology designed to improve the use of medical tubing in hospitals. The platform technology was developed to increase the safety and satisfaction of patients, caregivers, and healthcare facilities, while dramatically reducing costs. The company’s initial products include the Orchid SRV for use in IV catheter therapy and the Orchid SRV Type D device for use in surgical/wound, nephrostomy and abscess drainage. For more information, visit linearsciences.com.

____________________
1 Moreau, N. Impact and Safety Associated with Accidental Dislodgement of Vascular Access Devices: A Survey of Professions, Settings, and Devices. Journal of the Association for Vascular Access (2018) 23 (4): 203–215. https://doi.org/10.1016/j.java.2018.07.002

Contacts

Sam Choinski
Pazanga Health Communications
schoinski@pazangahealth.com
(860) 301-5058

Social Media Profiles

Contacts

Sam Choinski
Pazanga Health Communications
schoinski@pazangahealth.com
(860) 301-5058